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Effective treatments for androgen-independent prostate cancer (AIPCa) are lacking. To address this, emerging therapeutics such as
proteasome inhibitors are currently undergoing clinical trials. Inositol hexakisphosphate (IP6) is an orally non-toxic phytochemical that
exhibits antitumour activity against several types of cancer including PCa. We have previously shown that treatment of PC3 cells with
IP6 induces the transcription of a subset of nuclear factor-kB (NF-kB)-responsive and pro-apoptotic BCL-2 family genes. In this study,
we report that although NF-kB subunits p50/p65 translocate to the nucleus of PC3 cells in response to IP6, inhibition of NF-kB-
mediated transcription using non-degradable inhibitor of kB( I kB)-a does not modulate IP6 sensitivity. Treatment with IP6 also leads
to increased protein levels of PUMA, BIK/NBK and NOXA between 4 and 8h of treatment and decreased levels of MCL-1 and
BCL-2 after 24h. Although blocking transcription using actinomycin D does not modulate PC3 cell sensitivity to IP6, inhibition of
protein translation using cycloheximide has a significant protective effect. In contrast, blocking proteasome-mediated protein
degradation using MG-132 significantly enhances the ability of IP6 to reduce cellular metabolic activity in both PC3 and DU145 AIPCa
cell lines. This effect of combined treatment on mitochondrial depolarisation is particularly striking and is also reproduced by another
proteasome inhibitor (ALLN). The enhanced effect of combined MG132/IP6 treatment is almost completely inhibited by
cycloheximide and correlates with changes in BCL-2 family protein levels. Altogether these results suggest a role for BCL-2 family
proteins in mediating the combined effect of IP6 and proteasome inhibitors and warrant further pre-clinical studies for the treatment
of AIPCa.
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Prostate cancer (PCa) remains one of the leading causes of cancer-
related death in North-American men (Jemal et al, 2007). Though
localised forms of the disease can often be successfully treated by
surgery or radiotherapy, a significant proportion of patients having
undergone such interventions are at risk of disease recurrence.
Androgen deprivation therapy can prolong the life expectancy of
these patients; however, androgen-independent (AI) PCa (AIPCa)
eventually arises. As currently available treatment options for
AIPCa are lacking, there is a growing need for novel therapeutics
that can be effective against this advanced stage of the disease.
Inhibitors of the proteasome are showing promise as anticancer
agents against several cancers. Although the proteasome harbours
active sites for several types of proteolytic activity, these inhibitors
generally consist of small synthetic peptides targeting the
chymotryptic activity of the proteasome, which is thought to be
a rate-limiting catalytic step in proteasome-mediated protein
degradation (Lee and Goldberg, 1998). Notably, one proteasome
inhibitor (bortezomib) has been recently approved by both the
Food and Drug Administration (USA) and the European Agency
for Evaluation of Medicinal products for the treatment of recurrent
multiple myeloma and is currently undergoing clinical trials for
AIPCa (Papandreou and Logothetis, 2004; Papandreou et al, 2004;
Price and Dreicer, 2004; Zavrski et al, 2007).
Some studies have suggested that a major downstream target of
proteasome inhibition is nuclear factor-kB (NF-kB), a transcrip-
tion factor involved in the transcriptional regulation of hundreds
of genes implicated in cell proliferation, differentiation and cell
survival (Chen and Greene, 2004). Nuclear factor-kB is a dimeric
protein composed of homo- or heterodimers of p50, p65 (RelA),
p52, RelB and c-Rel subunits. Nuclear factor-kB activity is directly
regulated by the action of inhibitor of kB( I kB) proteins (e.g., IkB-a,
-b,- e and p100) and IkB kinases (Hoffmann et al, 2002; Karin et al,
2002; Buss et al, 2004). Inhibitors of kB retain NF-kB in the
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scell cytoplasm and diminish its transactivation potential, whereas
IkB kinases phosphorylate both IkBs as well as NF-kBi t s e l f .
Importantly, phosphorylation of IkBs by IKKs leads to their
proteasome-mediated degradation and to the release and nuclear
translocation of NF-kB subunits (classically p50/p65). Alternately, in
what is referred to as the non-canonical pathway, the proteasome
catalyses the processing of p100 into the NF-kB p52 subunit, which
may also translocate to the nuclear compartment (Karin and Ben-
Neriah, 2000; Karin et al, 2002; Chen and Greene, 2004).
More recently, proteasome inhibitors have also been found to
upregulate the expression of BCL-2 family proteins. Notably, pro-
apoptotic BH3-only proteins such as NOXA, BIK/NBK, BIM and
PUMA see their levels increased following treatment with
proteasome inhibitors such as MG-132, ALLN, lactacystin and
bortezomib (Marshansky et al, 2001; Nikrad et al, 2005; Zhu et al,
2005; Qin et al, 2006; Concannon et al, 2007). In parallel,
antiapoptotic proteins such as MCL-1 can also be upregulated
following proteasome inhibition, leading investigators to combine
proteasome inhibitors with strategies aimed at thwarting the
antiapoptotic response with some success (Qin et al, 2006).
BCL-2 family proteins play a major role in the control of
mitochondrial permeability. Importantly, mitochondrial outer-
membrane permeation (MOMP) is a key event in cell death
whether by means of apoptosis or necrosis (Kroemer et al, 2007).
Although the role of pro-apoptotic proteins, BAX and BAK, in this
process is clear, the nature of how these are activated to initiate
MOMP is currently under debate. In particular, how BH3-only
BCL-2 family proteins initiate BAX/BAK-assisted mitochondrial
permeability pore formation remains unclear. It has been
suggested that a subset of BH3-only proteins act as sensitisers to
the action of other BH3-only proteins thought to play the role of
BAX/BAK activators (Willis and Adams, 2005). Other recent
evidences suggest that BH3-only proteins, such as NOXA, BAD and
BIK/NBK, may act as inactivators of antiapoptotic BCL-2/BCL-XL
and MCL-1, preventing their inhibitory interaction with activator
BH3-only proteins such as PUMA, BID and BIM (Kim et al, 2006).
In either event, it is clear that the increased activity of pro-
apoptotic BH3-only proteins is important for the initiation of cell
death by various stimuli.
Inositol hexakisphosphate (IP6) is a naturally occurring
phytochemical abundant in soy and legumes that exhibits antic-
ancer activity in a wide range of cancers (Vucenik and
Shamsuddin, 2003). Although definite mechanisms have yet to
be established, IP6 activity has been reported to involve several
processes (Fox and Eberl, 2002). In DU145 AIPCa cells, IP6 has
been suggested to inhibit phosphatidyl inositol-3-kinase, prevent
epidermal growth factor receptor signalling through the mitogen-
activated protein kinase signalling cascade (Zi et al, 2000) and
diminish constitutive NF-kB activity (Agarwal et al, 2003). Still, in
the context of DU145 cells, IP6 was found to modulate cdk–cyclin
and pRb/E2F complexes leading to p21 and p27 upregulation and
cell cycle arrest in G1 (Singh et al, 2003).
Treatment of AIPCa cells with IP6 can also induce classic
hallmarks of apoptotic death such as caspase-3 activation, cleavage
of poly ADP-ribose polymerase, increased cell-surface phosphati-
dylserine and DNA fragmentation (Singh et al, 2003; Diallo et al,
2006). In LNCaP cells, treatment with IP6 was found to increase the
expression of pro-apoptotic BAX while decreasing the levels of
antiapoptotic BCL-2 (Agarwal et al, 2004). In addition, we have
recently shown that in PC3 cells, IP6 induces the mRNA expression
of PUMA, NOXA and BAX as well as a subset of NF-kB-responsive
genes including IkB-a and IRF-2 (Diallo et al, 2006). As such, we
hypothesised that the upregulation of NF-kB-responsive genes as
well as of genes coding for pro-apoptotic proteins could play a role
in mediating the pro-apoptotic effects of IP6 in PC3 cells. In this
study, we investigated the role of NF-kB and BCL-2 family
members in IP6-induced cell death. We also evaluated whether IP6
could be useful in combination with proteasome inhibitors.
MATERIALS AND METHODS
Cell culture
PC3 and DU145 cell lines were obtained from ATCC (Manassas, VA,
USA). Cells were maintained in RPMI-1640 complemented with 10%
foetal calf serum, gentamicin (50mgml
 1) and amphotericin B
(250ngml
 1) (Gibco-BRL, Frederick, MD, USA). Cell cultures were
incubated at 371Ci nah u m i d i f i e d5 %C O 2 atmosphere and
subcultured at 1:3 (LNCaP) or 1:5 (PC3, 22Rv1, DU145) by
trypsinisation with 0.25% trypsin for 5–10min at 371C( G i b c o - B R L ) .
Drugs and inhibitors
Inositol hexakisphosphate (Myo-Inositol hexakisphosphate dodeca-
sodium salt; Sigma-Aldrich, St Louis, MO, USA) was kept as a 100mM
stock solution diluted in water. Actinomycin D (Sigma-Aldrich) was
dissolved in DMSO and kept as a 1mgml
 1 stock solution.
Cycloheximide (Supelco, Bellefonte, PA, USA) stock solution
(50mgml
 1) was dissolved in ethanol. MG-132 (Calbiochem, San
Diego, CA, USA) was also diluted in ethanol as a 20mM stock
solution. ALLN (Calbiochem) was reconstituted in DMSO and kept at
a stock concentration of 10mM.
Cell seeding and treatments
For WST-1 assays, whole-cell extracts, nuclear/cytoplasmic ex-
tracts, RNA extractions and for 5,50,6,60-tetrachloro-1,10,3,30-
tetraethyl-benzimidazolcarbocyanide iodide (JC-1) assays, a simi-
lar cell-seeding procedure was used. Briefly, cells were trypsinised
and counted on a haemocytometer, then diluted in the appropriate
media at 200000 cells per ml and distributed in 96-well plates
(100ml per well for WST-1 and luciferase reporter assays) or six-
well plates (2ml per well for JC-1 assay and RNA extractions). For
whole-cell and nuclear/cytoplasmic extracts, cells (at a density of
200000 cells per ml) were seeded in 60mm petris (3ml per petri),
100mm petris (5ml per petri) or 150mm petris (10ml per petri).
Cells were allowed to adhere overnight before treatment. For the
experiments assessing the effects of dominant-negative (DN) IkB-a
on IP6 efficacy, cells were transfected with DN-IkB-a (pCMV-IkB-
aM; Clontech, Palo Alto, CA, USA) or control plasmid pCMV-Neo
(Clontech) 24h before seeding. Efficacy of DN-IkB-a transfection
was verified in parallel by luciferase assay (see below). Cells were
then treated with the indicated concentrations of IP6. In the
experiments where the effect of actinomycin D, cycloheximide,
MG-132, cycloheximideþMG-132 and ALLN on the activity of IP6
was assessed, cells were pre-treated 4h before the addition of IP6.
WST-1 metabolic assay
After a 24-h treatment with IP6 (in addition to treatment with the
appropriate inhibitors where indicated), 10ml of WST-1 reagent
(Roche, Nutley, NJ, USA) was added to wells and plates were
incubated at 371C in a humidified 5% CO2 atmosphere. Incubation
times were optimised for each cell line as recommended by the
manufacturer. WST-1 signal was measured on a Bio-Rad Model
3550 microplate reader at 450nm with reference at a wavelength of
655nm. Following data acquisition, cell metabolic activity was
calculated by first subtracting the readout of the WST-1 back-
ground (mediaþWST-1) from all values. For each independent
experiment, the median of the replicates was calculated for each
treatment. Subsequently, relative metabolic activity was calculated
as being the median WST-1 readout of the drug-treated well/
median WST-1 readout of vehicle-treated well. In the cases where
cells were pre-treated with an inhibitor (actinomycin D, cyclohex-
imide or MG-132), values were normalised relative to the
inhibitor-treated well that was not challenged with IP6. Cellular
metabolic activity was plotted as a function of IP6 concentration.
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sProtein extracts
Cells were scraped in their media, collected by centrifugation and
washed twice with cold PBS. Pellets were frozen at  801C.
Subsequently, whole-cell extractions were performed by applying
cold lysis buffer (10mM Tris-Hcl (pH 7.4), 150mM NaCl, 1mM
EDTA, 1mM DTT, 1mM NaF, 0.5% NP-40, 10mgml
 1 aprotinin,
2mgml
 1 leupeptin, 2mgml
 1 pepstatin, 10mmoll
 1 phenyl-
methylsulphonyl fluoride and 200mmoll
 1 orthovanadate) on ice
for 30min. Whole-cell extracts were collected after centrifugation
in a Heraeus Biofuge (13000r.p.m. for 10min at 41C) and were
immediately stored at  801C. Protein concentration was measured
by Bradford assays (Bio-Rad Laboratories Inc., Hercules, CA, USA)
according to the manufacturer’s instructions.
Nuclear and cytoplasmic protein extracts
After cell treatments, media were aspirated, cells were scraped and
washed twice with cold PBS, and pellets were frozen at  801C. Ice-
cold buffer I (10mmoll
 1 Hepes, 50mmoll
 1 NaCl, 10mmoll
 1
EDTA and 5mmoll
 1 MgCl2) with freshly added protease and
phosphatase inhibitors (10mgml
 1 aprotinin, 2mgml
 1 leupeptin,
2mgml
 1 pepstatin, 10mmoll
 1 phenylmethylsulphonyl fluoride
and 200mmoll
 1 orthovanadate) was added and cells were
incubated on ice for 30min. Cell membranes were lysed by
incubating with 1% NP-40 for 10min. Cytosolic fractions were
collected after centrifugation (3000g for 5min at 41C). Ice-cold
buffer II (10mmoll
 1 Hepes, 400mmoll
 1 NaCl, 0.1mmoll
 1
EDTA, 0.5mmoll
 1 and DTT) with freshly added protease and
phosphatase inhibitors was then added to the nuclear aggregates
and incubated on ice for 1h. Nuclear protein fractions were
collected after centrifugation (14000g for 15min at 41C). Each
fraction was immediately stored at  801C.
Antibodies
Antibodies recognising NOXA (OP180) and PUMA (PC686) were
obtained from Calbiochem. Antibodies detecting BAX (N-20, sc-
493), BCL-2 (C-2, sc-7382), BIK/NBK (N-19, sc-1710), MCL-1 (H-
260, sc-20679), RAN (C-20, sc-1156), IkB-a (C-21, sc-371), NF-kB
p65 (F-6, sc-8008), a-tubulin (TU-02, sc-8035), as well as horse-
radish peroxidase-conjugated secondary antibodies were obtained
from Santa Cruz Biotechnology (Santa Cruz, CA, USA). The anti-
NF-kB p50 (06-886) antibody was purchased from Upstate (Lake
Placid, NY, USA). Antibodies recognising b-actin (AC-15, ab6276)
and GAPDH (ab-9485) were obtained from Abcam (Cambridge,
MA, USA).
Western blot analysis
For western blot analyses, 20–75mg of whole-cell protein or
nuclear/cytoplasmic protein extracts were resolved on 10–17%
polyacrylamide gels and then transferred onto nitrocellulose or
PVDF membranes at 60V for 1–2h. Blots were blocked using 5%
non-fat dry milk in PBS–Tween 0.1% buffer for 2h at room
temperature. Membranes were then probed using antibodies
recognising PUMA (1:1000), NOXA (1:200), BAX (1:1000),
MCL-1 (1:100), BIK/NBK (1:200), BCL-2 (1:200), RAN
(1:3000), IkB-a (1:1000), NF-kB p65 (1:750), NF-kB p50
(1:750), a-tubulin (1:1000), b-actin (1:10000) and GAPDH
(1:5000). Membranes were then incubated with appropriate
secondary antibodies conjugated to horseradish peroxidase
(Amersham Life Sciences Inc., Arlington Heights, IL, USA) in
blocking buffer for 45min at room temperature and developed
with enhanced chemiluminescence (ECL) substrate (Amersham
Life Sciences Inc.). When necessary, membranes were stripped
using the protocol described in the ECL kit (Amersham Life
Sciences Inc.) and re-probed. Densometric analysis was performed
using the BioRad Quantity Ones software (CA, USA).
Quantitative real-time PCR
After the indicated times of treatment with IP6 and/or actinomycin
D, media were removed and RNA was extracted with Trizol reagent
according to the manufacturers’ instructions (Invitrogen, Burling-
ton, ON, Canada). Concentration of RNA samples was determined
using a Beckman DU-600 spectrophotometer. RNA (2mg) was used
to synthesise a cDNA using the SuperScript first-strand synthesis
system (random hexamer method) according to the manufac-
turer’s instructions (Invitrogen). The QuantiTect SYBR Green PCR
kit was used as recommended (Qiagen, Mississauga, ON, Canada).
Real-time PCRs were performed on a Rotor-gene RG-300 (Corbett
Research, Sydney, Australia). Optimal threshold and reaction
efficiency were determined using the Rotor-gene software. Melt
curves for each primer exhibited a single peak, indicating specific
amplification, which was also confirmed by agarose gel. Ct values
were determined using the Rotor-gene software at the optimal
threshold previously determined for each primer. Relative IkB-a/
actin B ratios were calculated using the Pfaffl method (Pfaffl, 2001).
Fold induction was calculated relative to the vehicle-treated
control. Experiments were performed twice and real-time mea-
surements were carried out in duplicate. Primer sequences used
were described earlier (Diallo et al, 2006).
JC-1 mitochondrial depolarisation assay
PC3 cells were incubated with 10mgml
 1 of JC-1 (Molecular
Probes, Eugene, OR, USA) at 371C in a humidified 5% CO2
atmosphere for 15min. Cells were washed twice with PBS and
trypsinised with 500ml 0.25% trypsin for 10min. Cells were then
collected and put in fluorescence-activated cell sorting (FACS)
counting tubes containing 500ml RPMI-1640 complemented with
10% FCS. JC-1 emission was measured in individual cells using a
Coulter Epics
s XL-MCL. The fold change in cells presenting de-
polarised mitochondria (green shift in JC-1 fluorescence) was
calculated relative to vehicle-treated control for each time point.
Luciferase reporter assays
PC3 cells were seeded at 400000 cells per ml in 60mm petris
(3ml). The following morning, lipofectamine PLUS reagent
(Invitrogen) was used to transfect 1mg pCMV-IkB-aM (or
pCMV-Neo control), 0.8mg of a 3enh-kB-ConA-luc green lucifer-
ase reporter (or control ptkGL3 luciferase gene driven by a
minimal thymidine kinase promoter) and 0.2mg of a pCMV-RL
Renilla luciferase reporter (Promega, Madison, WI, USA). The
following day, transfected cells were re-seeded at a density of
20000 cells per well in 96-well plates. To assess the effects of MG-
132 on kB-luc activity, transfected cells were then treated with MG-
132 for 24h after which time green and renilla luciferase activity
was assayed using the dual luciferase reporter assay system
(Promega) on a Victor
3 luminometer/fluorimeter (Perkin Elmer,
ON, Canada). To calculate the relative kB reporter activity, green
luciferase activity was first normalised according to renilla
luciferase output (transfection efficacy control) and then corrected
for background effects by subtracting the basal activity detected
from the ptkGL3 plasmid. The 3enh-kB-ConA-luc (hereby referred
to as kB-luc), carrying a firefly luciferase gene under the control of
a trimer of kB consensus, was a kind gift from Dr Juana Wietzerbin
(Institut Curie, Paris, France). To construct the ptkGL3 control
plasmid, the SV40 promoter (BglII/HindII fragment) was removed
from the pGL3 basic plasmid (Promega) and a minimal thymidine
kinase promoter (BglII/HindIII fragment) from the pNF-kB-
d2EGFP plasmid (Clontech) was inserted in its place.
Enhanced effect of IP6 and proteasome inhibitors
J-S Diallo et al
1615
British Journal of Cancer (2008) 99(10), 1613–1622 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sStatistics
Averages, standard errors of the mean and P-values (calculated
using t-test) were calculated from individual experiments. The
number of replicates as well as the number of independent
experiments are indicated in the figure legends. All statistical tests
were performed in Excel (Microsoft
s, WA, USA). For WST-1
assays, an effect was deemed significant when a P-value o0.05 was
reached for at least one concentration of IP6.
RESULTS
IP6 induces NF-jB nuclear translocation in PC3 cells
We have previously observed that a subset of NF-kB-responsive
genes is upregulated in response to IP6 in PC3 cells. Notably, we
have found that IkB-a mRNA levels can increase up to 20-fold
following a 24-h treatment with 2mM IP6 (Diallo et al, 2006),
beginning as early as 4h post-treatment (data not shown). As IkB-a
is thought to be regulated by p50/p65 NF-kB subunits (Sun et al,
1993), we set out to determine the effects of IP6 on NF-kB subunit
nuclear translocation. Figure 1A shows that although only minimal
changes in the status of p52 and its precursor p100 could be
observed, nuclear p50 and p65 increased substantially following a
24h treatment with IP6 (Figure 1A), an event that was visible as
early as 4h following challenge with IP6 (data not shown). Notably,
the increase in nuclear p50/p65 was not due to contamination from
cytoplasmic proteins, as evidenced by the absence of a-tubulin in
the nuclear extracts (Figure 1A). In contrast to observations at the
mRNA level (Diallo et al, 2006), a slight decrease in IkB-a protein
(which was primarily located in the cytoplasm) was detected in
parallel (Figures 1A and 3). Overall, these data indicated that
canonical NF-kB subunits translocate to the nucleus in response to
treatment with IP6.
Reduced NF-jB transcriptional activity by expression of a
non-degradable IjB-a does not modulate the response to
IP6
Others have reported that in DU145 cells, NF-kB nuclear
translocation decreases in response to IP6, resulting in a reduced
NF-kB DNA-binding activity (Agarwal et al, 2003). Consequently,
the observation that NF-kB p50 and p65 translocate to the nucleus
in response to IP6 in PC3 cells led us to ask whether the
modulation of NF-kB-mediated transcription was implicated in the
activity of IP6 in PC3 cells. To address this, we transfected PC3
cells with a non-degradable DN mutant of IkB-a (Brown et al,
1995) (DN-IkB-a) or a control vector (pCMVNeo) and determined
whether this could modulate the effects of IP6. As shown in
Figure 1B, the transient transfection of DN-IkB-a effectively
reduced NF-kB transcriptional activity relative to the pCMVNeo
control as assessed using the kB-luc reporter. However, WST-1
assays indicate that DN-IkB-a- and pCMVNeo-transfected PC3
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Figure 1 (A) IP6 induces canonical NF-kB subunit nuclear translocation.
Nuclear (N) and cytoplasmic (C) extracts of PC3 cells, treated with vehicle
(0mM) or IP6 (2mM) for 24h, were probed by western blot to assess the
expression and subcellular localisation of p100, p52, IkB-a, p50 and p65. a-
Tubulin was used as a control for nuclear extract purity. b-Actin was used
as a loading control. (B) A non-degradable dominant-negative form of IkB-
a inhibits NF-kB transcriptional activity. DN-IkB-a or pCMVNeo control
plasmids were co-transfected with kB-luc/Renilla luciferase in PC3 cells. kB-
luc activity was measured after 72h and normalised according to renilla and
basal tkGL3 activity (see Materials and Methods). Data represent average of
two independent experiments performed in four to eight replicates each.
*P-value o0.05. (C) Inhibition of NF-kB transcriptional activity does not
modulate the efficacy of IP6. PC3 cells, transiently transfected (48h) with
pCMVNeo and DN-IkB-a cells, were plated at a density of 20000 cells per
well and treated with increasing doses of IP6. Metabolic activity was
measured using WST-1 reagent and relative metabolic activity was
normalised according to vehicle-treated pCMVNeo- or DN-IkB-a-
transfected cells (see Materials and Methods). Data represent average of
two independent experiments performed in three to six replicates each.
Error bars represent the standard error.
t0 t4 t8 t24
2 mM IP6
MCL-1
BCL-2
BIK/NBK
IB-
PUMA
NOXA
BAX
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−+− +− +
Figure 2 IP6 modulates the expression of BCL-2 family proteins. PC3
cells were treated with 2mM IP6 or vehicle and whole-cell extracts were
prepared from cells harvested upon treatment (t0) and after 4h (t4) and
8h (t8) of additional treatment with IP6 (þ) or vehicle ( ). Western
blotting was used to probe extracts for MCL-1, BCL-2, IkB-a, BIK/NBK,
PUMA, NOXA and BAX expression. RAN expression was used as a
loading control. Solid boxes signal increased protein levels in treated cells as
compared with time-matched control cells, whereas dashed boxes indicate
decreased protein levels relative to time-matched controls. Blot was
representative of two independent experiments each performed in
duplicate.
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scells respond similarly to a challenge with IP6 (Figure 1C). While
not excluding any potential effects of reduced NF-B activity on cell
proliferation (Diallo et al, 2006), this suggests that reduced NF-kB
transcriptional activity does not protect from or enhance the
cytotoxic effects of IP6.
IP6 modulates BCL-2 family protein expression
In parallel with NF-kB-responsive genes, we have previously
reported that the mRNA levels of BCL-2 family pro-apoptotic
genes such as NOXA, PUMA and BAX increase in response to IP6
(Diallo et al, 2006). Hence, we next set out to determine how the
protein levels of these pro-apoptotic BCL-2 family proteins
changed in time following treatment with IP6. To address this,
PC3 cells were challenged with 2mM IP6, and whole-cell extracts
were prepared after 4, 8 and 24h of continuous treatment. The
extracts were then probed by western blot. As shown in Figure 2,
the expression of PUMA increased as early as 4h following
treatment with IP6 until at least 8h post-treatment. Similarly, an
increased NOXA expression was also observed although later (8h)
and to a lesser extent. Both PUMA and NOXA expression
subsequently returned to normal after 24h of treatment with
IP6. In contrast, no clear changes in BAX protein expression were
observed. We also looked at whether protein expression of other
pro- and antiapoptotic BCL-2 family members could be modulated
in response to IP6. As can be seen in Figure 2, BIK/NBK expression
is also upregulated by IP6 similarly to PUMA though to a lesser
extent, particularly at 4h. In contrast, we could observe a
decreased expression of antiapoptotic proteins MCL-1 and BCL-
2, though only after 24h of treatment with IP6. These data
suggested that IP6 induces temporal changes in the ratio of pro-
and antiapoptotic BCL-2 family proteins.
Protein synthesis is important for IP6-induced cytotoxicity
In light of the results presented in Figure 2, in addition to our
observation of increased mRNA expression of pro-apoptotic BCL-2
family members in a previous study (Diallo et al, 2006), we next set
out to determine whether transcriptional upregulation of pro-
apoptotic genes, such as PUMA, NOXA and potentially BIK/NBK,
could be important for mediating the effects of IP6. To gain an
overall appreciation for this, we compared the efficacy of IP6 in
PC3 cells pre-treated (4h) with an inhibitor of mRNA transcription
(Yamamoto et al, 1980) or vehicle (DMSO). Figure 3A shows that
continuous treatment with actinomycin D, starting 4h before the
addition of IP6 (for 24h), did not modulate PC3 cell sensitivity to
IP6. To verify that actinomycin D effectively blocked mRNA
synthesis in our conditions, we looked at the mRNA levels of IkB-a
in response to IP6. Figure 3B shows that IP6-induced IkB-a
upregulation after 24h of treatment was effectively blocked by
actinomycin D, but not by DMSO. As IP6 treatment could lead to
protein upregulation independently of transcription, we next
assessed the efficacy of IP6 in PC3 cells where protein production
was blocked using cycloheximide (50mgml
 1, 4h pre-treatment).
Figure 3C shows that a continuous treatment with the translation
inhibitor cycloheximide (Yamamoto et al, 1980), starting 4h
before treatment with IP6, significantly protected from IP6-
Effect of actinomycin D on IP6 cytotoxicity
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Figure 3 (A) A transcription inhibitor does not protect PC3 cells from the effects of IP6. Actinomycin D (1mgml
 1)- and DMSO-pre-treated PC3 cells
(density of 20000 cells per well) were treated with increasing doses of IP6 for 24h. Metabolic activity was measured after 24h (plus 4-h pre-treatment)
using WST-1, and the data were normalised according to DMSO- or actinomycin D-pre-treated cells not treated with IP6. Data represent average of five
independent experiments each performed in three to six replicates. No significant difference was observed between actinomycin D- and DMSO-treated
cells. (B) Actinomycin D inhibits IP6-induced upregulation of IkB-a mRNA. PC3 cells were pre-treated for 4h with 1mgml
 1 actinomycin D or DMSO, then
treated with 2mM IP6 or vehicle (0mM). cDNA was synthesised from RNA extracted 24h later and real-time PCR was used to measure the fold change in
IkB-a mRNA expression. Data represent an average of two independent experiments performed in duplicate. (C) An inhibitor of protein translation
protects PC3 cells from the effects of IP6. As in (B), cycloheximide (50mgml
 1)- and ethanol-pre-treated PC3 cells were treated with increasing doses of
IP6 for 24h and metabolic activity was measured using WST-1. Data represent an average of three independent experiments performed in three to six
replicates. Error bars represent the standard error. *P-value o0.05;
#P-value¼0.06.
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sinduced toxicity (Po0.05 at 1.5mM IP6). These data suggested a
role for protein synthesis in mediating the effects of IP6 and that
one possible effect of blocking protein translation would be to
hinder on the temporal shift of the ratio between pro-apoptotic to
antiapoptotic proteins induced by IP6.
A proteasome inhibitor sensitises androgen-independent
prostate cancer cells to the effects of IP6
As blocking protein translation reduced the efficacy of IP6,
potentially by preventing increases in pro-apoptotic protein levels,
we rationalised that blocking proteasome-mediated protein
degradation could have the opposite effect and instead enhance
the effect of IP6. To test this hypothesis, we treated PC3 AIPCa
cells with the commonly used proteasome inhibitor MG-132
(20mM) (Palombella et al, 1994), beginning 4h before the addition
of IP6, and assessed the efficacy of IP6 using WST-1 assays.
Figure 4A shows that over 24h, cells co-treated with MG-132 were
significantly more sensitive to IP6 treatment than control cells
(Po0.005, IP6 1mM). As inhibitors of the proteasome have been
reported to inhibit NF-kB transcriptional activity, we also assessed
the effect of MG-132 on kB-luc reporter activity in PC3 cells. We
found that, at least in the PC3 cell line, MG-132 did not inhibit
NF-kB-mediated transcription of the kB-luc reporter. In fact, a
slight increase in kB-luc reporter activity was detected with
increasing doses of MG-132 (Figure 4B). MG-132 co-treatment also
significantly sensitised DU145 AIPCa cells to the effects of IP6
(Figure 4C; Po0.01, IP6 1mM).
IP6 and proteasome inhibitors elicit enhanced
mitochondrial depolarisation in a protein
translation-dependent fashion
The potential involvement of one or more members of the BCL-2
family proteins in the observed effect of IP6 next prompted us to
look at whether a treatment with IP6 and/or proteasome inhibitors
initiated MOMP. To address this, we stained both treated and
control PC3 cells with JC-1 dye and used FACS to measure the
percentage of cells exhibiting a green shift in JC-1 fluorescence in
treated cells relative to the control at various time points following
treatment. Notably, a JC-1 fluorescence shift from red to green is
indicative of cells having undergone MOMP (Salvioli et al, 1997).
We found that IP6 (2mM) used alone caused a modest but time-
dependent increase in MOMP (Figure 5A–C). As we had observed
that cycloheximide protected from the effects of IP6 using WST-1
assays, we looked at whether cycloheximide (50mgml
 1) could
protect from IP6-induced MOMP. We found that cycloheximide on
its own could induce MOMP to an extent similar to what was
observed for IP6 (Figure 5A and C). However, co-treatment with
IP6 and cycloheximide did not further increase the amount of cells
exhibiting a green shift in JC-1 fluorescence (Figure 5A and C).
Similarly, we found that MG-132 used alone also caused a time-
dependent increase in green-shifted JC-1-stained cells. Although
likely due to the extra 4h of pre-treatment with MG-132, at 8h
(plus 4h ‘pre-treatment’), MG-132 appeared to induce roughly
twice the relative amount of MOMP as compared with IP6 (Figure
5A–C). Importantly, co-treatment with MG-132 and IP6 caused a
drastic increase in cells presenting MOMP. After 8h, cells co-
treated with IP6 and MG-132 had nearly three-fold the quantity of
cells exhibiting MOMP as compared with MG-132 alone and six-
fold the quantity of cells exhibiting MOMP as compared with
IP6-treated cells (Figure 5A–C). We next questioned whether the
observed enhanced effect of combined IP6 and MG-132 at the level
of MOMP was specific to MG-132 or whether it could also be
observed with other proteasome inhibitors. Figure 5B shows that
ALLN (10mM) (Schow and Joly, 1997) also enhances the induction
of MOMP when combined with IP6 in PC3 cells. To assess whether
the enhancement of MOMP, elicited by combined treatment with
IP6 and proteasome inhibitors, required de novo protein synthesis,
we co-treated cells with cycloheximide (50mgml
 1), MG-132
PC3
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Figure 4 The proteasome inhibitor MG-132 sensitises AIPCa cells to the effects of IP6. In (A) (PC3) and (C) (DU145), cells were plated at 20000 cells
per well and pre-treated for 4h with MG-132 (or ethanol control) before addition of IP6 at increasing concentrations. Metabolic activity was measured2 4h
later using WST-1. For each cell line, relative metabolic activity was calculated according to the WST-1 output MG-132-treated or control cells treated with
vehicle (0mM IP6). Data represent an average of three independent experiments performed in three to six replicates each. ***P-valueo0.005;
**P-valueo0.01;
#P-value¼0.08;
##P¼0.09. (B) As described in Figure 1C, kB-luc reporter and control-transfected cells were treated with 2 or 20mM
MG-132 or vehicle (CTRL) and assayed for relative luciferase activity. Data represent an average of two independent experiments performed in four to eight
replicates each. Error bars represent the standard error.
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s(20mM) and IP6 (2mM). We found that although the addition of
cycloheximide did not reduce MG-132-induced MOMP (Figure 5A
and C), the addition of cycloheximide almost completely blocked
the enhanced MOMP observed in response to combined treatment
with MG-132 and IP6 (Figure 5C).
MG-132 and cycloheximide modulate the expression of
BCL-2 family proteins in PC3 cells
As blocking of protein translation prevented MOMP in response to
combined IP6 and MG-132 treatment, we deemed it relevant to
look at how BCL-2 family member expression was modulated in
response to MG-132 and cycloheximide with and without IP6
(added 4h later). Western blotting of whole-cell extracts was used
to detect the expression of BCL-2 family members as well as IkB-a.
The results presented in Figure 6 suggest that treatment of PC3
cells with MG-132 substantially increased the levels of NOXA and,
to a lesser extent, of BIK/NBK, PUMA and MCL-1. The addition of
IP6 led to a slight further increase in the levels of NOXA, BIK/NBK
and MCL-1. In contrast, the treatment of PC3 cells with
cycloheximide on its own caused almost a complete loss of NOXA
expression and substantially decreased BIK/NBK and MCL-1
protein levels. Interestingly, subsequent addition of IP6 curtailed
the decrease in the levels of MCL-1 but not that of NOXA or BIK/
NBK. Cycloheximide did not modulate the expression of PUMA or
BAX when used alone although, notably, it did not completely
block IP6-induced upregulation of PUMA. Similar to MG-132,
cycloheximide used alone slightly decreased the expression of
IkB-a. However, the addition of IP6 to cycloheximide-treated cells
caused a further decrease in IkB-a. Although co-treating PC3 cells
with MG-132 and cycloheximide nullified their respective effects
on MCL-1 and BIK/NBK expression levels, reduced NOXA and
BCL-2 expression remained observable. Interestingly, the com-
bined treatment with MG-132 and cycloheximide reduced IkB-a
levels more than either treatment used alone, independently of IP6.
DISCUSSION
In contrast with studies performed using other cell lines (Ferry
et al, 2002; Agarwal et al, 2003), the data presented here suggest
that, at least in PC3 cells, classical NF-kB subunits p50 and p65
translocate to the nucleus up to 24h following treatment with IP6
(Figure 1A). In parallel, IkB-a protein levels slightly decrease in
response to IP6 (Figures 1A and 2), even though IkB-a mRNA
increases substantially over 24h (Diallo et al, 2006), beginning as
early as 4h post-treatment (data not shown). Although the IkB-a
gene is a well-known target of p50/p65, the IkB-a protein is
normally degraded upon activation of the classical pathway
following phosphorylation by IKK-b, leading to an autofeedback
loop (Karin and Ben-Neriah, 2000). Hence, our observations of
nuclear translocation of p50/p65, in parallel with decreased IkB-a
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Figure 5 IP6 and proteasome inhibitors present an enhanced effect on mitochondrial depolarisation. (A) PC3 cells were pre-treated with 50mgml
 1
cycloheximide (CHX), 20mM MG-132 (MG) or control ethanol and the percentage of cells presenting mitochondrial depolarisation according to JC-1
staining was assessed by FACS after 0, 2, 4 and 8h of treatment with 2mM IP6 (or vehicle). (B) PC3 cells were pre-treated with 20mM MG-132, 10mM ALLN
or DMSO before the addition of 2mM IP6 (or control). Eight hours later, the percentage of cells presenting mitochondrial depolarisation according to JC-1
staining was assessed by FACS. (C) PC3 cells were pre-treated with 20mM MG-132, 50mgml
 1 cycloheximide or a combination of MG-132 and
cycloheximide or control ethanol before addition of 2mM IP6 (or vehicle). Eight hours later, the percentage of cells presenting mitochondrial depolarisation
according to JC-1 staining was assessed by FACS. In (A–C), data were normalised according to the percentage of cells exhibiting mitochondrial
depolarisation according to the JC-1 staining observed in vehicle-treated controls. Data represent an average of two to three independent experiments. All
error bars represent the standard error.
Enhanced effect of IP6 and proteasome inhibitors
J-S Diallo et al
1619
British Journal of Cancer (2008) 99(10), 1613–1622 & 2008 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
sprotein and concomitant increase of IkB-a mRNA, are consistent
with the activation of the classical NF-kB pathway. This is further
reinforced by the observation that blocking protein production
using cycloheximide (which we expect would prevent any new IkB-
a from being produced) further decreased the expression of IkB-a
protein in response to IP6 (Figure 6). In contrast, we found that the
non-canonical pathway (p100/p52) is largely unaffected by
treatment with IP6. Although these results altogether suggest that
the NF-kB classical pathway may be triggered in response to
treatment of PC3 cells with IP6, inhibiting NF-kB transcriptional
activity (assessed by kB-luc assay, Figure 1B), by transfecting PC3
cells with a non-degradable DN form of IkB-a (Brown et al, 1995),
does not modulate PC3 cell sensitivity to IP6 (Figure 1C). Hence,
our results are at odds with the suggestion that IP6-induced cell
death is mediated by the inhibition of constitutive NF-kB activity.
On the basis of our results, a more likely possibility is that IP6
modulates BCL-2 family protein expression in a manner that leads
to an increased pro-apoptotic/antiapoptotic BCL-2 family protein
ratio. Indeed, Figure 2 shows that IP6 induced a gradual shift in
the levels of BCL-2 family members at the protein level, wherein
pro-apoptotic proteins such as PUMA, NOXA and BIK were
upregulated early on (4 and 8h) and where the levels of
antiapoptotic proteins such as MCL-1 and BCL-2 decreased
somewhere between 8 and 24h following treatment with IP6. As
we had previously observed the upregulation of PUMA, NOXA and
BAX mRNA, we initially hypothesised that this could be mediated
by the upregulation of pro-apoptotic genes at the mRNA level.
However, we were surprised to find that a transcription inhibitor
(Yamamoto et al, 1980), although effectively blocking IP6-induced
upregulation of gene expression (Figure 3B), did not protect cells
from the effects of IP6 (Figure 3A). As protein expression can be
modulated by post-transcriptional events including mRNA export,
mRNA translation and proteasome-mediated protein degradation,
it remained possible that the ratio of pro-apoptotic to antiapopto-
tic proteins could shift in response to IP6 independently of mRNA
transcription and actinomycin D. Indeed, PC3 cells in which
protein translation was blocked using cycloheximide were
significantly protected from the effects of IP6 (Figure 3C). At the
very least, these data suggest that protein translation is more
relevant than mRNA transcription in communicating the observed
effects of IP6. With respect to this, it is a likely possibility that the
effect of IP6 at least partially involves increased ratios of pro-
apoptotic to antiapoptotic BCL-2 family proteins.
One potential mechanism that could lead to an increased protein
production independently of transcription is that IP6 stabilises
pro-apoptotic proteins. For example, this could result from the
inhibition of specific ubiquitin ligases such as MULE/ARF-BP1
(that targets MCL-1 for degradation) (Zhong et al, 2005) or from
the direct inhibition of the proteasome. On the other hand, the
observed decrease in MCl-1, BCL-2 and IkB-a, after longer
exposure times of PC3 cells with IP6, argues against both of these
possibilities (Figure 2). Another potential mechanism is that IP6
stimulates ribosomal protein production of pro-apoptotic pro-
teins. Potential candidate targets that could mediate such an effect
of IP6 include mTOR and RalA, which have been recently found to
regulate the translation of the antiapoptotic protein FLIPS (Panner
et al, 2006). Notably, mTOR is well known to be regulated by Akt
(Dutcher, 2004), which in turn is also an upstream activator of
NF-kB (Karin and Ben-Neriah, 2000; Karin et al, 2002; Chen and
Greene, 2004), whose classical p50/p65 subunits translocate to the
nucleus in response to IP6 (Figure 1A). However, the activation of
mTOR is generally associated with an increased expression of
cyclin D1 and cell proliferation, not cell death (Dutcher, 2004).
Finally, reports showing that endogenous IP6 plays a role in mRNA
export (Alcazar-Roman et al, 2006; Weirich et al, 2006) suggest the
intriguing possibility that IP6 increases the cytoplasmic export of
existing pools of accumulated pro-apoptotic nuclear mRNA.
However, it is unclear whether the nuclear mRNA export
machinery is so specific as to allow for the export of pro-
apoptotic, but not antiapoptotic, BCL-2 family members.
Although the observed effect of cycloheximide on the efficacy of
IP6 and IP6/MG-132 co-treatment may involve de novo protein
synthesis, we cannot exclude the possibility that these observations
are linked with reductions in basal pro-apoptotic protein levels
resulting from pre-treatment with cycloheximide. Indeed, we can
observe decreased levels of NOXA and BIK/NBK in response to
treatment with cycloheximide alone (Figure 6, lane 3). However,
treatment with cycloheximide led to a similar decrease in
antiapoptotic MCL-1 (Figure 6). Surprisingly, we found that
MCL-1 levels decreased less in response to treatment with
cycloheximide when cells were subsequently treated with IP6
(Figure 6, compare lane 3 with 7). Analogously, IP6-induced
expression of PUMA was not fully inhibited in the presence of
cycloheximide (Figure 6, compare lane 4 with 7). This observation
is interesting in light of reports suggesting that cycloheximide
inhibits cytoplasmic ribosomes but not mitochondrial ribosomes,
which are of notably different composition (Bruce and Kerry,
1987). Although relatively little is known about nuclear mRNA
sorting to the mitochondria (Sylvestre et al, 2003), mitochondrial
import of nuclear tRNAs is better described and is required for
mitochondrial protein translation (Verner, 1993; Kamenski et al,
2007). It is tempting to speculate that certain BCL-2 family
proteins can be synthesised by mitochondrial ribosomes from
imported cytoplasmic mRNAs.
Following from our observations in Figures 2 and 3, we
rationalised that if blocking the production of pro-apoptotic
BCL-2 family proteins by treatment with cycloheximide reduced
IP6 efficacy, then increasing their levels using proteasome
inhibitors may lead to an enhanced effect. Indeed, we found that
co-treatment with MG-132 significantly increased the effect of IP6
in at least two AIPCa cell lines (Figure 4A and B). Our results
suggest that this effect is not due to the inhibition of NF-kB
transcriptional activity as treatment of PC3 cells with MG-132
increased NF-kB transcription from a kB-luc reporter (Figure 4B)
and reduced IkB-a protein levels (Figure 6, lanes 4 and 8). This is
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Figure 6 Modulation of BCL-2 family protein expression in PC3 cells in
response to IP6. MG-132 (MG) and cycloheximide (CHX). PC3 cells were
pre-treated for 4h with 20mM MG-132, 50mgml
 1 cycloheximide or both.
Cells were then challenged with 2mM IP6 (or control) for 4h after which
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loading control. The presented blots were representative of three
independent experiments each performed in duplicate.
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sconsistent with other studies that have reported that at least in
some cells, proteasome inhibitors do not inhibit NF-kB but instead
increase the expression of BIK/NBK, while levels of BAX and BAK
remain stable (Zhu et al, 2005). Indeed, we found that MG-132
clearly increased the levels of NOXA, BIK/NBK and MCL-1, but
levels of BAX remained stable. Interestingly, treatment of PC3 cells
with cycloheximide led to decreased levels of NOXA, BIK/NBK and
MCL-1, suggesting that these may be quickly synthesised and
degraded equally rapidly by the proteasome. As MG-132 has been
reported to mainly inhibit chymotryptic proteasome activity, this
may also suggest that the degradation of IkB-a in prostate cells
could be mediated by peptidylglutamyl peptide-hydrolysing,
trypsin-like, or even caspase-like, proteasome-associated activities
(Lee and Goldberg, 1998; Groll et al, 1999). In contrast, NOXA,
BIK/NBK and MCL-1 may be the preferred clients of the
chymotryptic active site.
The observation that blocking protein translation using
cycloheximide almost completely inhibits MOMP induced by
combined IP6- and proteasome-inhibitor treatment strongly
points to the involvement of pro-apoptotic BCL-2 family members.
In particular, proteins with potentially rapid degradation kinetics,
such as NOXA and BIK/NBK, which are further increased by
treatment with IP6 (albeit only slightly), may act in concert to elicit
this enhanced effect on mitochondrial depolarisation. At the same
time, it must be noted that antiapoptotic MCL-1 also seems to
respond, particularly, to combined MG-132 and IP6 treatment.
With respect to this, it will be interesting to determine whether a
MCL-1-targeting siRNA can further enhance the efficacy of
combined IP6/proteasome inhibitor treatment. Notably, others
were able to increase the potency of bortezomib using this MCL-1
knockdown approach in melanoma cells (Qin et al, 2006).
In light of the multitude of pro-apoptotic BCL-2 family
members, it is likely that other BCL-2 family members are also
upregulated by both IP6 and MG-132, further perturbing the pro-
apoptotic/antiapoptotic ratio. It is equally possible that a subset of
pro-apoptotic proteins is specifically upregulated by IP6, whereas
another complementary subset is upregulated by MG-132. This
could lead to an enhanced cytotoxicity according to a recently
proposed hierarchical BCL-2 family model of BAX/BAK activation.
In this model, some BH3-only proteins such as NOXA, BAD, BMF
and BIK/NBK may act upstream of ‘activator-only’ pro-apoptotic
proteins such as BID, BIM and PUMA, by releasing them from the
inhibitory clutches of antiapoptotic BCL-2/BCL-XL and MCL-1
(Kim et al, 2006). In this context, the combined upregulation of
NOXA and BIK/NBK by MG-132 may complement the upregula-
tion of activator-only proteins following challenge with IP6.
Although PUMA was a potential candidate, its expression also
appears to be increased by MG-132 (Figure 6, lane 2). In fact, levels
of PUMA in cells treated with the combination of IP6 and MG-132
appeared closer to that observed in cells treated with MG-132 alone
(Figure 6, lane 6). These levels were notably lower than those seen
when treating cells with IP6 alone (Figure 6, lane 5), perhaps
suggesting that the effect of MG-132 on PUMA protein levels is
dominant over that of IP6. In addition, our attempts to prevent the
enhanced cytotoxic effects of combined IP6 and MG-132 treatment
by shRNA-mediated downregulation of PUMA have proved
unsuccessful so far (data not shown). Hence, the net level of
PUMA protein is not a likely mediator of this combined effect.
Rather, we suspect that one or more pro-apoptotic ‘activator-only’
proteins not probed for here may be upregulated by IP6 but not by
MG-132, or that, alternately, IP6 induces post-translational
modifications that activate pro-apoptotic proteins upregulated by
MG-132. We are currently investigating these possibilities.
Nonetheless, the enhanced effect of IP6 was seen with two
different proteasome inhibitors. This was most clearly visible when
MOMP was assessed in individual PC3 cells using JC-1 dye (Figure
5A–C). In addition to the observation that combining IP6 with
MG-132 leads to an enhanced effect in both PC3 and DU145 cell
lines, these results suggest that IP6 may be useful in combination
with proteasome inhibitor drugs for treatment of AIPCa. This
possibility is particularly exciting as proteasome inhibitors are
already undergoing pre-clinical trials for AIPCa (Papandreou and
Logothetis, 2004; Papandreou et al, 2004; Price and Dreicer, 2004)
and as previous studies have also shown that IP6 can exhibit
anticancer activity in mice when administered as a dietary
supplement in drinking water (Singh et al, 2004).
CONCLUSION
In conclusion, we find that NF-kB does not likely play a major role
in either preventing or promoting the cytotoxic effects of IP6 in PC3
cells. We propose that the upregulation of pro-apoptotic BCL-2
family members at the protein level is likely involved in skewing the
pro-apoptotic/antiapoptotic protein ratio and in mediating the
cytotoxic effects of IP6. Finally, we conclude that proteasome
inhibitors enhance the effect of IP6 on mitochondrial depolarisation,
potentially involving multiple pro-apoptotic BCL-2 family members.
Altogether, our results suggest that the pre-clinical evaluation of
proteasome inhibitors in combination with IP6 is warranted and
could provide an alternative for the treatment of AIPCa.
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